Journal of the American Academy of Dermatology
Volume 61, Issue 6 , Pages 971-976 , December 2009

A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor

  • Jan Faergemann, MD, PhD

      Affiliations

    • Department of Dermatology, Sahlgrenska University Hospital, Göteborg, Sweden
    • Corresponding Author InformationReprint requests: Jan Faergemann, MD, PhD, Barrier Therapeutics, Cipalstraat 3, B-2440 Geel, Belgium.
    • ,
  • Gail Todd, MBChB

      Affiliations

    • Groote Schuur Hospital, Observatory, Cape Town, South Africa
    • ,
  • Sandrakantha Pather, MBChB

      Affiliations

    • Skin Centre, University Cape Town, Lung Institute, Cape Town, South Africa
    • ,
  • Zubar F.A. Vawda, MBChB

      Affiliations

    • private practice, Durban, South Africa
    • ,
  • John D. Gillies, MBChB

      Affiliations

    • P3 Research Ltd, Tauranga, New Zealand
    • ,
  • Ted Walford, MBChB

      Affiliations

    • P3 Research Ltd, Tauranga, New Zealand
    • ,
  • Charles Barranco, BA

      Affiliations

    • Barrier Therapeutics Inc, Princeton, New Jersey
    • ,
  • John N. Quiring, PhD

      Affiliations

    • QST Consultations Ltd, Allendale, Michigan
    • ,
  • Manuel Briones, MD

      Affiliations

    • Francisco Bolonã, Guayaquil, Ecuador

,Accepted 18 August 2008.

References 

  1. Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000;1:75–80
  2. Odds F, Ausma J, Van Gerven F, Woestenborghs F, Meerpoel L, Heeres J, et al. In vitro and in vivo activities of the novel azole antifungal agent R126638. Antimicrob Agents Chemother. 2004;48:388–391
  3. Meerpoel L, Backx LJ, Van der Veken LJ, Heeres J, Corens D, De Groot A, et al. Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. J Med Chem. 2005;48:2184–2193
  4. Vanden Bossche H, Ausma J, Bohets H, Vermuyten K, Willemsens G, Marichal P, et al. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004;48:3272–3278
  5. Piérard-Franchimont C, Ausma J, Wouters L, Vroome V, Vandeplassche L, Borgers M, et al. Activity of the triazole antifungal R126638 as assessed by corneofungimetry. Skin Pharmacol Physiol. 2006;19:50–56
  6. Faergemann J, Ausma J, Borgers M. The in vitro activity of R126638 and ketoconazole against Malassezia species. Acta Derm Venereol. 2006;86:312–315
  7. Faergemann J, Ausma J, Vandeplassche L, Borgers M. The efficacy of oral treatment with pramiconazole in pityriasis versicolor: a phase IIa trial. Br J Dermatol. 2007;156:1385–1388
  8. Mesens JL, Putteman P, Verheyen P. Pharmaceutical applications of 2-hydroxypropyl-ß-cyclodextrin. In:  Duchene D editors. New trends in cyclodextrins and derivatives. Paris: Editions de Sante; 1991;p. 369–407
  9. Stevens DA. Itraconazole in cyclodextrin solution. Pharmacotherapy. 1999;19:603–611
  10. Walsh TJ, Viviani MA, Arathoon E, Chiou C, Ghannoum M, Groll AH, et al. New targets and delivery systems for antifungal therapy. Med Mycol. 2000;38(Suppl):335–347

 Supported by Barrier Therapeutics, Inc.

 Conflicts of interest: None declared.

PII: S0190-9622(08)01075-X

doi: 10.1016/j.jaad.2008.08.033

Journal of the American Academy of Dermatology
Volume 61, Issue 6 , Pages 971-976 , December 2009

Article Tools

* Image Usage & Resolution